Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 23, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

August 24, 2021

Conditions
Deep Vein ThrombosisPulmonary EmbolismVenous Thromboembolism
Interventions
DRUG

Standard heparin dose

Patients will be placed on heparin infusions per their surgeon's discretion.

DRUG

Real time heparin dose adjustment

Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.

Trial Locations (1)

84112

University of Utah, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT03516656 - Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin | Biotech Hunter | Biotech Hunter